Cover Image
Market Research Report

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 363124
Published Content info 85 Pages
Delivery time: 1-2 business days
Price
Back to Top
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2019
Published: April 29, 2019 Content info: 85 Pages
Description

Summary:

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Central Nervous System, Gastrointestinal, Respiratory and Immunology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Metastatic Colorectal Cancer, Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Colon Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis and Prostate Cancer.

The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2019, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
  • The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1863TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
    • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • American Gene Technologies International Inc
    • Auritec Pharmaceuticals Inc
    • Bristol-Myers Squibb Co
    • Cytodyn Inc
    • Merck & Co Inc
    • Novartis AG
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
    • (cenicriviroc + tropifexor) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (emtricitabine + tenofovir disoproxil fumarate) + maraviroc SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-1105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-813160 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leronlimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OB-002H - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OB-002M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OB-002O - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vicriviroc - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2019: ASM Microbe 2019 Conference grants both poster and oral presentations to CytoDyn for its pivotal study of Leronlimab (PRO 140) which demonstrated superior efficacy and safety in heavily treatment-experienced HIV patients
      • Apr 01, 2019: CytoDyn announces data from two studies at the AACR Annual Meeting
      • Mar 28, 2019: Orion Biotechnology to present OB-002 in vitro potency data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019
      • Mar 26, 2019: CytoDyn's leronlimab performs well as a monotherapy for HIV
      • Mar 26, 2019: CytoDyn's monotherapy trial with Leronlimab (PRO 140) exceeds expectations
      • Mar 18, 2019: CytoDyn reaches historical milestone, submits first of three sections of BLA to FDA for leronlimab (PRO 140) as a combination therapy for HIV
      • Mar 12, 2019: Orion Biotechnology Canada announces three new appointments to their senior management team
      • Mar 11, 2019: CytoDyn reports significant reduction in Breast Cancer Tumor Metastasis in preclinical study and requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)
      • Mar 04, 2019: FDA grants rolling review for CytoDyn's planned BLA for investigational HIV Therapy Leronlimab (PRO 140)
      • Feb 27, 2019: CytoDyn to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019
      • Feb 20, 2019: CytoDyn announces Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks
      • Feb 14, 2019: American Gene Technologies signs research agreement with NIAID for Experimental HIV/AIDS Cure Strategy
      • Feb 12, 2019: Researchers at Queen's University Belfast have developed a vaginal ring capable of providing sustained delivery of OB-002 (5P12-RANTES) for HIV prevention
      • Feb 01, 2019: CytoDyn announces productive conference call with FDA regarding first BLA Submission for Leronlimab (PRO 140) combination therapy at 700 mg Dose
      • Jan 29, 2019: Orion Biotechnology Canada report that IND- enabling studies evaluating the safety of their OB-002H microbicide gel have shown an excellent mucosal safety profile
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Indication, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Investigation by Universities/Institutes, H1 2019
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pipeline by Allergan Plc, H1 2019
  • Pipeline by American Gene Technologies International Inc, H1 2019
  • Pipeline by Auritec Pharmaceuticals Inc, H1 2019
  • Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Pipeline by Cytodyn Inc, H1 2019
  • Pipeline by Merck & Co Inc, H1 2019
  • Pipeline by Novartis AG, H1 2019
  • Dormant Products, H1 2019
  • Dormant Products, H1 2019 (Contd..1), H1 2019
  • Dormant Products, H1 2019 (Contd..2), H1 2019
  • Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Top 10 Indications, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top